Last reviewed · How we verify
scopolamin
At a glance
| Generic name | scopolamin |
|---|---|
| Sponsor | University Hospital, Angers |
| Target | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
- Allergic rhinitis
- Common cold
- Cough
- Cycloplegia
- Dilated pupil
- Iridocyclitis
- Irritable bowel syndrome
- Motion sickness
- Nasal congestion
- Nasal discharge
- Peptic ulcer
- Perioperative Mydriasis
- Posterior synechiae
- Prevention of Motion Sickness
- Prevention of Post-Operative Nausea and Vomiting
- Prevention of Posterior Synechiae
- Uveitis
- Vasomotor rhinitis
Common side effects
- Dry mouth
- Dizziness
- Somnolence
- Agitation
- Visual Impairment
- Confusion
- Mydriasis
- Pharyngitis
- Drowsiness
- Blurred vision
- Dilation of the pupils
- Headache
Serious adverse events
- Acute angle closure glaucoma
- Acute psychosis
- Hallucinations
- Disorientation
- Paranoia
- Eclamptic seizures
- Amnesia
- Coordination abnormalities
- Hyperthermia
- MRI skin burns
Key clinical trials
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Effect of Pre-medication in Pain Measures on Office Hysteroscopy (PHASE4)
- Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |